m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02597)
Name
[3H]cAMP
Synonyms
Cyclic AMP; cAMP; 60-92-4; Adenosine 3',5'-cyclic monophosphate; 3',5'-cyclic AMP; Adenosine 3',5'-phosphate; Adenosine 3',5'-cyclophosphate; cyclic 3',5'-AMP; Adenosine cyclic monophosphate; cyclic 3',5'-Adenylic acid; Adenosine 3',5'-monophosphate; Adenosine-3',5'-cyclophosphate; Adenosine cyclophosphate; Cyclic Adenosine Monophosphate; cyclic Adenosine 3',5'-phosphate; Cyclic adenylic acid; Adenosine cyclic 3',5'-monophosphate; 3',5'-AMP; cyclic Adenosine 3',5'-monophosphate; Adenosine cyclic 3',5'-phosphate; [3H]-cAMP
    Click to Show/Hide
Status
Investigative
Structure
Formula
C10H12N5O6P
InChI
1S/C10H12N5O6P/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7-4(20-10)1-19-22(17,18)21-7/h2-4,6-7,10,16H,1H2,(H,17,18)(H2,11,12,13)/t4-,6-,7-,10-/m1/s1
InChIKey
IVOMOUWHDPKRLL-KQYNXXCUSA-N
PubChem CID
6076
TTD Drug ID
D0UB2J
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
cAMP-dependent protein kinase A type I (PRKAR1A)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary cAMP-dependent protein kinase A type I (PRKAR1A) is a therapeutic target for [3H]cAMP. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of [3H]cAMP through regulating the expression of cAMP-dependent protein kinase A type I (PRKAR1A). [1], [2]
References
Ref 1 FTO-Dependent N (6)-Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling. Cancer Res. 2020 Aug 15;80(16):3200-3214. doi: 10.1158/0008-5472.CAN-19-4044. Epub 2020 Jun 30.
Ref 2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.